Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
复制标题
DOI：
10.1007/s00125-018-4729-5
复制
发表时间：
2018-12-01
期刊：
影响因子：
8.2
通讯作者：
Buse, John B.
中科院分区：
文献类型：
--
作者：
Davies, Melanie J.;D'Alessio, David A.;Buse, John B.
美国糖尿病协会和欧洲糖尿病研究协会召集了一个小组，更新2012年和2015年发表的关于成人2型糖尿病管理的先前立场声明。对2014年以来的文献进行了系统评价，提出了新的建议。这些措施包括对生活方式管理和糖尿病自我管理教育和支持的额外关注。对于肥胖者，建议以减肥为目标，包括生活方式、药物和手术干预。在药物管理方面，对于临床心血管疾病患者，建议使用钠-葡萄糖共转运体2(SGLT2)抑制剂或胰升糖素样肽1(GLP-1)受体激动剂，已证实对心血管有益。对于患有慢性肾脏疾病或临床心力衰竭和动脉粥样硬化性心血管疾病的患者，建议使用已证实有效的SGLT2抑制剂。GLP-1受体激动剂通常被推荐为第一批可注射药物。美国糖尿病协会和欧洲糖尿病研究协会召集了一个小组，更新2012年和2015年发表的关于成人2型糖尿病管理的先前立场声明。对2014年以来的文献进行了系统评价，提出了新的建议。这些措施包括对生活方式管理和糖尿病自我管理教育和支持的额外关注。对于肥胖者，建议努力减肥，包括生活方式、药物和手术干预。在药物管理方面，对于临床心血管疾病患者，建议使用钠-葡萄糖共转运体-2(SGLT2)抑制剂或胰高血糖素样肽-1(GLP-1)受体激动剂，已证实对心血管有益。对于患有慢性肾脏疾病或临床心力衰竭和动脉粥样硬化性心血管疾病的患者，建议使用已证实有效的SGLT2抑制剂。GLP-1受体激动剂通常被推荐作为第一种注射用药。
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.